Joanne D Stekler1, George Ure2, Joshua D O'Neal3, Aric Lane4, Fred Swanson5, Janine Maenza2, Claire Stevens2, Robert W Coombs6, Joan Dragavon7, Paul D Swenson4, Matthew R Golden8. 1. Departments of Medicine, University of Washington, Seattle, WA, United States; Departments of Epidemiology, University of Washington, Seattle, WA, United States; Public Health-Seattle & King County, Seattle, WA, United States. Electronic address: jstekler@uw.edu. 2. Departments of Medicine, University of Washington, Seattle, WA, United States. 3. San Francisco AIDS Foundation, San Francisco, CA, United States. 4. Public Health-Seattle & King County, Seattle, WA, United States. 5. Gay City Health Project, Seattle, WA, United States. 6. Departments of Medicine, University of Washington, Seattle, WA, United States; Departments of Laboratory Medicine, University of Washington, Seattle, WA, United States. 7. Departments of Laboratory Medicine, University of Washington, Seattle, WA, United States. 8. Departments of Medicine, University of Washington, Seattle, WA, United States; Departments of Epidemiology, University of Washington, Seattle, WA, United States; Public Health-Seattle & King County, Seattle, WA, United States.
Abstract
BACKGROUND AND OBJECTIVE: The rapid test study was a real-time comparison of point-of-care (POC) HIV tests to determine their abilities to detect early HIV infection. STUDY DESIGN: Men and transgender persons reporting sex with men in the prior year were recruited at the Public Health-Seattle & King County STD Clinic, Gay City Health Project, and University of Washington Primary Infection Clinic. Study tests included the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test performed on oral fluids and tests performed on fingerstick whole blood specimens including OraQuick, Uni-Gold Recombigen HIV test, Determine HIV-1/2 Ag/Ab Combo, and INSTI HIV-1 Rapid Antibody Test. Specimens from subjects with negative results were sent for EIA and nucleic acid amplification testing. McNemar's exact tests compared the numbers of HIV-infected subjects detected. RESULTS: Between February 2010 and August 2014, there were 3438 study visits. Twenty-four subjects had discordant POC results with at least one reactive and one non-reactive test, including one subject with a reactive Determine p24 antigen. OraQuick performed on oral fluids identified fewer persons compared to all fingerstick tests. OraQuick performed on fingerstick whole blood detected fewer persons compared to the Determine Combo antibody component (p=.008) and Combo overall (p=.004), and there was a trend when compared to INSTI (p=.06). The Determine Combo specificity was 98.99%. CONCLUSIONS: As reported by others, Determine Combo underperforms compared to laboratory-based testing, but it did detect one acute infection. If these results are validated, the specificity of Determine Combo may limit its usefulness in populations with lower HIV incidence.
BACKGROUND AND OBJECTIVE: The rapid test study was a real-time comparison of point-of-care (POC) HIV tests to determine their abilities to detect early HIV infection. STUDY DESIGN:Men and transgender persons reporting sex with men in the prior year were recruited at the Public Health-Seattle & King County STD Clinic, Gay City Health Project, and University of Washington Primary Infection Clinic. Study tests included the OraQuick ADVANCE Rapid HIV-1/2 Antibody Test performed on oral fluids and tests performed on fingerstick whole blood specimens including OraQuick, Uni-Gold Recombigen HIV test, Determine HIV-1/2 Ag/Ab Combo, and INSTI HIV-1 Rapid Antibody Test. Specimens from subjects with negative results were sent for EIA and nucleic acid amplification testing. McNemar's exact tests compared the numbers of HIV-infected subjects detected. RESULTS: Between February 2010 and August 2014, there were 3438 study visits. Twenty-four subjects had discordant POC results with at least one reactive and one non-reactive test, including one subject with a reactive Determine p24 antigen. OraQuick performed on oral fluids identified fewer persons compared to all fingerstick tests. OraQuick performed on fingerstick whole blood detected fewer persons compared to the Determine Combo antibody component (p=.008) and Combo overall (p=.004), and there was a trend when compared to INSTI (p=.06). The Determine Combo specificity was 98.99%. CONCLUSIONS: As reported by others, Determine Combo underperforms compared to laboratory-based testing, but it did detect one acute infection. If these results are validated, the specificity of Determine Combo may limit its usefulness in populations with lower HIV incidence.
Authors: Frances H Priddy; Christopher D Pilcher; Renee H Moore; Pradnya Tambe; Mahin N Park; Susan A Fiscus; Mark B Feinberg; Carlos del Rio Journal: J Acquir Immune Defic Syndr Date: 2007-02-01 Impact factor: 3.731
Authors: Christopher D Pilcher; Susan A Fiscus; Trang Q Nguyen; Evelyn Foust; Leslie Wolf; Del Williams; Rhonda Ashby; Judy Owen O'Dowd; J Todd McPherson; Brandt Stalzer; Lisa Hightow; William C Miller; Joseph J Eron; Myron S Cohen; Peter A Leone Journal: N Engl J Med Date: 2005-05-05 Impact factor: 91.245
Authors: Joanne D Stekler; Paul D Swenson; Robert W Coombs; Joan Dragavon; Katherine K Thomas; Catherine A Brennan; Sushil G Devare; Robert W Wood; Matthew R Golden Journal: Clin Infect Dis Date: 2009-08-01 Impact factor: 9.079
Authors: Mark W Pandori; John Hackett; Brian Louie; Ana Vallari; Teri Dowling; Sally Liska; Jeffrey D Klausner Journal: J Clin Microbiol Date: 2009-06-17 Impact factor: 5.948
Authors: Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch Journal: AIDS Date: 2003-09-05 Impact factor: 4.177
Authors: T Déirdre Hollingsworth; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks; Christophe Fraser Journal: J Infect Dis Date: 2014-12-26 Impact factor: 5.226
Authors: Lauren R Violette; Andy Cornelius-Hudson; Madison Snidarich; Lisa A Niemann; Sonny Michael Assennato; Allyson Ritchie; Neha Goel; Pollyanna R Chavez; Steven F Ethridge; David A Katz; Helen Lee; Kevin P Delaney; Joanne D Stekler Journal: J Acquir Immune Defic Syndr Date: 2022-04-15 Impact factor: 3.771
Authors: Joanne D Stekler; Kenneth Tapia; Janine Maenza; Claire E Stevens; George A Ure; Joshua D O'Neal; Aric Lane; James I Mullins; Robert W Coombs; Sarah Holte; Ann C Collier Journal: AIDS Res Hum Retroviruses Date: 2018-06-13 Impact factor: 2.205
Authors: David A Katz; Matthew R Golden; James P Hughes; Carey Farquhar; Joanne D Stekler Journal: J Acquir Immune Defic Syndr Date: 2018-08-15 Impact factor: 3.731
Authors: Wei Luo; David A Katz; Susan Cassels; Deven T Hamilton; Jennie McKenney; Samuel M Jenness; Steven M Goodreau; Joanne D Stekler; Eli S Rosenberg; Patrick S Sullivan Journal: JMIR Public Health Surveill Date: 2018-06-29
Authors: Joanne D Stekler; Lauren R Violette; Lisa Niemann; Vanessa M McMahan; David A Katz; Jared M Baeten; Robert M Grant; Kevin P Delaney Journal: Open Forum Infect Dis Date: 2018-09-26 Impact factor: 3.835